Single-photon emission computed tomography in diagnosis and differential diagnosis of Parkinson's disease

Neurodegenerative Diseases

Volumn 7, Issue 5, 2010, Pages 319-329

  Isaias, Ioannis U ^a,b   Antonini, Angelo ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b PARKINSON INSTITUTE   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

Differential diagnosis; Essential tremor; Parkinson's disease; Single photon emission computed tomography

Indexed keywords

BRADYKINESIA; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ESSENTIAL TREMOR; HUMAN; MUSCLE RIGIDITY; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPTOMATOLOGY; TREMOR; ANIMAL; DYSKINESIA, DRUG-INDUCED; EARLY DIAGNOSIS; MOVEMENT (PHYSIOLOGY); PHYSIOLOGY; SCINTISCANNING;

ANIMALS; DIAGNOSIS, DIFFERENTIAL; DYSKINESIA, DRUG-INDUCED; EARLY DIAGNOSIS; HUMANS; MOVEMENT; PARKINSON DISEASE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREMOR;

EID: 77954264557     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000314498     Document Type: Review

References (212)

1. Gelb DJ, Oliver E, Gilman S: Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56: 33-39.
2. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ: The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125: 861-870.
3. Jankovic J, Rajput AH, McDermott MP, Perl DP: The evolution of diagnosis in early Parkinson's disease. Parkinson Study Group. Arch Neurol 2000; 57: 369-372.
4. Meara J, Bhowmick BK, Hobson P: Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing 1999; 28: 99-102.
5. Dickson DW, Braak H, Duda JE, et al: Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 2009; 8: 1150-1157.
6. Newman EJ, Breen K, Patterson J, Hadley DM, Grosset KA, Grosset DG: Accuracy of Parkinson's disease diagnosis in 610 general practice patients in the West of Scotland. Mov Disord 2009; 24: 2379-2385.
7. Arvanitakis Z, Wilson RS, Schneider JA, et al: Diabetes mellitus and progression of rigidity and gait disturbance in older persons. Neurology 2004; 63: 996-1001.
8. Inzelberg R, Jankovic J: Are Parkinson disease patients protected from some but not all cancers? Neurology 2007; 69: 1542-1550.
9. Gibb WR, Lees AJ: The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 745-752.
10. Bezard E, Dovero S, Prunier C, et al: Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2, 3,6-tet rahydropyr idine-lesioned macaque model of Parkinson's disease. J Neurosci 2001; 21: 6853-6861.
11. Seibyl JP, Marek KL, Quinlan D, et al: Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995; 38: 589-598.
12. Seibyl JP, Marek K, Sheff K, et al: Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients. J Nucl Med 1997; 38: 1453-1459.
13. Abi-Dargham A, Gandelman MS, DeErausquin GA, et al: SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. J Nucl Med 1996; 37: 1129-1133.
14. Booij J, Tissingh G, Winogrodzka A, et al: Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease. Eur J Nucl Med 1997; 24: 68-71.
15. Tzen KY, Lu CS, Yen TC, Wey SP, Ting G: Differential diagnosis of Parkinson's disease and vascular parkinsonism by (99m)Tc-TRODAT-1. J Nucl Med 2001; 42: 408-413.
16. Weng YH, Yen TC, Chen MC, et al: Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects. J Nucl Med 2004; 45: 393-401.
17. Riederer P, Wuketich S: Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm 1976; 38: 277-301.
18. Hornykiewicz O, Kish SJ: Biochemical pathophysiology of Parkinson's disease. Adv Neurol 1987; 45: 19-34.
19. Fearnley JM, Lees AJ: Ageing and Parkinson's disease: SN regional selectivity. Brain 1991; 114: 2283-2301.
20. Tissingh G, Bergmans P, Booij J, et al: Drugnaive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]-[beta]-CIT SPECT. J Neurol 1998; 245: 14-20.
21. Tissingh G, Booij J, Bergmans P, et al: Iodine-123-N-omega-fluoropropyl- 2-beta-carbomethoxy-3-beta-[4-iodophenyl]tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease. J Nucl Med 1998; 39: 1143-1148. (Pubitemid 28326141)
22. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ: Measuring the rate of progression and estimating the premotoral period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 1998; 64: 314-319.
23. Marek K, Innis R, van Dyck C, et al: [123I] B-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 2001; 57: 2089-2094.
24. Brucke T, Asenbaum S, Pirker W, et al: Measurement of the dopaminergic denervation in Parkinson's disease with [123I]-b-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neurol Transm 1997; 50: 9-24.
25. Antonini A, Moeller JR, Nakamura T, Spetsieris P, Dhawan V, Eidelberg D: The metabolic anatomy of tremor in Parkinson's disease. Neurology 1998; 51: 803-810.
26. Benamer HTS, Patterson J, Grosset DG: Accurate differentiation of parkinsonism and essential tremor using visual assessment of [ 123 I]FP-CIT SPECT imaging: The [ 123 I]FPCIT SPECT study group. Mov Disord 2000; 15: 503-510.
27. Berding G, Brücke T, Odin P, et al: [123I]beta-CIT SPECT imaging of dopamine and serotonin transporters in Parkinson's disease and multiple system atrophy. Nuklearmedizin 2003; 42: 31-38.
28. Hesse S, Oehlwein C, Barthel H, Schwarz J, Polster D, Wagner A, Sabri O: Possible impact of dopamine SPECT on decision-making for drug treatment in Parkinsonian syndrome. J Neural Transm 2006; 113: 1177-1190.
29. Isaias IU, Benti R, Cilia R, et al: [123I]FP-CIT striatal binding in early Parkinson's disease patients with tremor vs akinetic-rigid onset. Neuroreport 2007; 18: 1499-1502.
30. Spiegel J, Hellwig D, Samnick S, et al: Striatal FP-CIT uptake differs in the subtypes of early Parkinson's disease. J Neural Transm 2007; 114: 331-335.
31. Rossi C, Volterrani D, Nicoletti V, et al: 'Parkinson-dementia' diseases: a comparison by double tracer SPECT studies. Parkinsonism Relat Disord 2009; 15: 762-766.
32. Müller U, Wächter T, Barthel H, Reuter M, von Cramon DY: Striatal [123I]-CIT SPECT and prefrontal cognitive functions in Parkinson's disease. J Neural Transm 2000; 107: 303-319.
33. Nobili F, Abbruzzese G, Morbelli S, et al: Amnestic mild cognitive impairment in Parkinson's disease: a brain perfusion SPECT study. Mov Disord 2009; 24: 414-421.
34. Staffen W, Mair A, Unterrainer J, Trinka E, Ladurner G: Measuring the progression of idiopathic Parkinson's disease with [123I]-CIT SPECT. J Neural Transm 2000; 107: 543-552.
35. Chouker M, Tatsch K, Linke R, Pogarell O, Hahn K, Schwarz J: Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years. Nucl Med Commun 2001; 22: 721-725.
36. Parkinson Study Group: Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson disease progression. JAMA 2002; 287: 1653-1661.
37. Winogrodzka A, Bergmans P, Booij J, van Royen EA, Janssen AG, Wolters EC: [123I] FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease. J Neural Transm 2001; 108: 1011-1019.
38. Colloby SJ, Williams ED, Burn DJ, et al: Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT. Eur J Nucl Med Mol Imaging 2005; 32: 1176-1185.
39. Isaias IU, Marotta G, Shikegi H, et al: Imaging essential tremor. Mov Disord 2010; 25: 679-686.
40. Brooks DJ, Frey KA, Marek KL, et al: Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol 2003; 184: 68-79.
41. Brooks DJ: Imaging end points for monitoring neuroprotection in Parkinson's disease. Ann Neurol 2003; 53: 110-118.
42. Marek K, Jennings D, Seibyl J: Dopamine agonists and Parkinson's disease progression: what can we learn from neuroimaging studies. Ann Neurol 2003; 53: 160-166.
43. Morrish PK: How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease. Mov Disord 2003; 18: 63-70.
44. Seibyl J, Jennings D, Tabamo R, Marek K: Neuroimaging trials of Parkinson's disease progression. J Neurol 2004; 251: 9-13.
45. Ravina B, Eidelberg D, Ahlskog JE, et al: The role of radiotracer imaging in Parkinson disease. Neurology 2005; 64: 208-215.
46. Djaldetti R, Treves TA, Ziv I, Melamed E, Lampl Y, Lorberboym M: Use of a single [(123)I]-FP-CIT SPECT to predict the severity of clinical symptoms of Parkinson disease. Neurol Sci 2009, Epub ahead of print.
47. Whone AL, Watts RL, Stoessl AJ, et al: Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003; 54: 93-101.
48. Morrish PK: Real-PET and CONSORT. Ann Neurol 2003; 54: 692-693.
49. Marek K, Jennings D, Seibyl J: Long-term follow-up of patients with scans without evidence of dopaminergic deficit (SWEDD) in the ELLDOPA study. Neurology 2005; 64:A274.
50. Schneider SA, Edwards MJ, Mir P, et al: Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov Disord 2007; 22: 2210-2215.
51. Pirker W, Djamshidian S, Asenbaum S, et al: Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal-CIT SPECT study. Mov Disord 2002; 17: 45-53.
52. Marshall VL, Patterson J, Hadley DM, Grosset KA, Grosset DG: Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging. Nucl Med Commun 2006; 27: 933-937.
53. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E: Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
54. Braune S, Reinhardt M, Schnitzer R, Riedel A, Lücking CH: Cardiac uptake of [123I] MIBG separates Parkinson's disease from multiple system atrophy. Neurology 1999; 53: 1020-1025.
55. Courbon F, Brefel-Courbon C, Thalamas C, et al: Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease. Mov Disord 2003; 18: 890-897.
56. Taki J, Yoshita M, Yamada M, Tonami N: Significance of 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: it can be a specific marker for Lewy body disease. Ann Nucl Med 2004; 18: 453-461.
57. Matsui H, Nishinaka K, Oda M, Komatsu K, Kubori T, Udaka F: Does cardiac metaiodobenzylguanidine (MIBG) uptake in Parkinson's disease correlate with major autonomic symptoms? Parkinsonism Relat Disord 2006; 12: 284-288.
58. Iwasa K, Nakajima K, Yoshikawa H, Tada A, Taki J, Takamori M: Decreased myocardial 123I-MIBG uptake in Parkinson's disease. Acta Neurol Scand 1998; 97: 303-306.
59. Orimo S, Takahashi A, Uchihara T, Mori F, Kakita A, Wakabayashi K, Takahashi H: Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson's disease. Brain Pathol 2007; 17: 24-30.
60. Taki J, Nakajima K, Hwang EH, et al: Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. Eur J Nucl Med 2000; 27: 566-573.
61. Spiegel J, Möllers MO, Jost WH, et al: FP-CIT and MIBG scintigraphy in early Parkinson's disease. Mov Disord 2005; 20: 552-561.
62. Spiegel J, Hellwig D, Farmakis G, et al: Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson's disease. Mov Disord 2007; 15: 1004-1008.
63. Sawada H, Oeda T, Yamamoto K, et al: Diagnostic accuracy of cardiac metaiodobenzylguanidine scintigraphy in Parkinson disease. Eur J Neurol 2009; 16: 174-182.
64. Lang AE, Obeso JA: Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 2004; 3: 309-316.
65. Ahlskog JE: Beating a dead horse: dopamine and Parkinson disease. Neurology 2007; 69: 1701-1711.
66. Delong MR, Wichmann T: Circuits and circuit disorders of the basal ganglia. Arch Neurol 2007; 64: 20-24. (Pubitemid 46072419)
67. Tolosa E, Gaig C, Santamaría J, Compta Y: Diagnosis and the premotor phase of Parkinson disease. Neurology 2009; 72(suppl): 12-20.
68. Gonera EG, Van't Hof M, Berger HJ, Van Weel C, Horstink MW: Symptoms and duration of the premotor phase in Parkinson's disease. Mov Disord 1997; 12: 871-876.
69. Becker G, Müller A, Braune S, et al: Early diagnosis of Parkinson's disease. J Neurol 2002; 3: 40-48.
70. Chaudhuri KR, Healy DG, Schapira AH, National Institute for Clinical Excellence: Nonmotor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006; 3: 235-245.
71. Chaudhuri KR, Martinez-Martin P: Quantitation of non-motor symptoms in Parkinson's disease. Eur J Neurol 2008; 15: 2-7.
72. Marras C, Lang A: Changing concepts in Parkinson disease: Moving beyond the Decade of the Brain. Neurology 2008; 70: 1996-2003.
73. Tolosa E, Gaig C, Santamaría J, Compta Y: Diagnosis and premotor phase of Parkinson disease. Neurology 2009; 72:S12-S20.
74. Pearce RK, Hawkes CH, Daniel SE: The anterior olfactory nucleus in Parkinson's disease. Mov Disord 1995; 10: 283-287.
75. Abbott RD, Ross GW, White LR, et al: Environmental, life-style, and physical precursors of clinical Parkinson's disease: recent findings from the Honolulu-Asia aging study. J Neurol 2003; 250: 30-39.
76. Iranzo A, Molinuevo JL, Santamaría J, et al: Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 2006; 5: 572-577.
77. Marek KL, Seibyl JP, Zoghbi SS, et al: [ 123 I]-CIT/SPECT demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996; 46: 231-237.
78. Jennings DL, Seibyl JP, Oakes D, Eberly S, Murphy J, Marek K: (123I)-CIT and singlephoton emission computed tomography imaging vs. clinical evaluation in parkinsonian syndromes: unmasking an early diagnosis. Arch Neurol 2004; 61: 1224-1229.
79. Ponsen MM, Stoffers D, Booij J, van Eck-Smit BLF, Wolters EC, Berendse HW: Idiopathic hyposmia as preclinical sign of Parkinson's disease. Ann Neurol 2004; 56: 173-181.
80. Ponsen MM, Stoffers D, Wolters EC, Booij J, Berendse HW: Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson's disease. Neurol Neurosurg Psychiatry 2010; 81: 396-399.
81. Iranzo A, Santamaria J, Rye DB, et al: Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD. Neurology 2005; 65: 247-252.
82. Stiasny-Kolster K, Doerr Y, Möller JC, et al: Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 2005; 128: 126-137.
83. Jennings D, Siderow A, Stern M, Marek K: The PARS study: recruitment of a cohort at risk for Parkinson's disease. Mov Disord 2008; 23:S193-S194.
84. Aarsland D, Karlsen K: Neuropsychiatric aspects of Parkinson's disease. Curr Psychiatry Rep 1999; 1: 61-68.
85. Antonini A: Unraveling depression in Parkinson's disease. Eur J Neurol 2008; 15: 885-886.
86. Owens MJ, Nemeroff CB: Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 1994; 40: 288-295.
87. Innis R, Baldwin R, Sybirska E, et al: Single photon emission computed tomography imaging of monoamine reuptake sites in primate brain with [123I]CIT. Eur J Pharmacol 1991; 200: 369-370.
88. Laruelle M, Baldwin RM, Malison RT, et al: SPECT imaging of dopamine and serotonin transporters with [123I]-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 1993; 13: 295-309.
89. Hesse S, Meyer PM, Strecker K, et al: Monoamine transporter availability in Parkinson's disease patients with or without depression Eur J Nucl Med Mol Imaging 2009; 36: 428-435.
90. Kuikka JT, Bergstrom KA, Ahonen A, et al: Comparison of iodine-123 labelled 2 betacarbomethoxy-3 beta-(4-iodophenyl)tropane and 2 beta-carbomethoxy-3 beta-(4-iodophenyl)-N-(3-fluoropropyl) nortropane for imaging of the dopamine transporter in the living human brain. Eur J Nucl Med 1995; 22: 356-360.
91. Fujita M, Takatoku K, Matoba Y, et al: Differential kinetics of [123I]beta-CIT binding to dopamine and serotonin transporters. Eur J Nucl Med 1996; 23: 431-436.
92. Tiihonen J, Kuikka JT, Bergstrom KA, et al: Single-photon emission tomography imaging of monoamine transporters in impulsive violent behavior. Eur J Nucl Med 1997; 24: 1253-1260.
93. Malison RT, Price LH, Berman R, et al: Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl) tropane and single photon emission computed tomography. Biol Psychiatry 1998; 44: 1090-1098.
94. Meltzer CC, Smith G, DeKosky ST, et al: Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging. Neuropsychopharmacology 1998; 18: 407-430.
95. Staley JK, Malison RT, Innis RB: Imaging of the serotonergic system: interactions of neuroanatomical and functional abnormalities of depression. Biol Psychiatry 1998; 44: 534-549.
96. Willeit M, Praschak-Rieder N, Neumeister A, et al: [123I]-beta-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder. Biol Psychiatry 2000; 47: 482-489.
97. Kim SE, Lee WY, Choe YS, Kim JH: SPECT measurement of iodine-123-beta-CIT binding to dopamine and serotonin transporters in Parkinson's disease: correlation with symptom severity. Neurol Res 1999; 21: 255-261.
98. Murai T, Muller U, Werheid K, et al: In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2001; 13: 222-228.
99. Boileau I, Warsh JJ, Guttman M, et al: Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C]DASB. Mov Disord 2008; 23: 1776-1780.
100. Albin RL, Koeppe RA, Bohnen NI, Wernette K, Kilbourn MA, Frey KA: Spared caudal brainstem SERT binding in early Parkinson's disease. J Cereb Blood Flow Metab 2008; 28: 441-444.
101. Kish SJ, Tong J, Hornykiewicz O, Rajput A, Chang LJ, Guttman M, Furukawa Y: Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 2008; 131: 120-131.
102. Bergstrom KA, Halldin C, Hall H, et al: In vitro and in vivo characterization of norbeta-CIT: a potential radioligand for visualization of the serotonin transporter in the brain. Eur J Nucl Med 1997; 24: 596-601.
103. Blough BE, Abraham P, Mills AC, et al: 3 Beta-(4-ethyl-3-iodophenyl) nortropane-2 beta-carboxylic acid methyl ester as a highaffinity selective ligand for the serotonin transporter. J Med Chem 1997; 40: 3861-3864.
104. Hiltunen J, Akerman KK, Kuikka JT, et al: Iodine-123 labeled nor-beta-CIT as a potential tracer for serotonin transporter imaging in the human brain with single-photon emission tomography. Eur J Nucl Med 1998; 25: 19-23.
105. Oya S, Kung M-P, Acton PD, et al: A new single-photon emission computed tomography imaging agent for serotonin transporters: [123I] IDAM, 5-Iodo-2-((2-((dimethyl-amino)methyl)phenyl)thio)benzyl alcohol. J Med Chem 1999; 42: 333-335.
106. Acton PD, Kung MP, Mu M, et al: Singlephoton emission tomography imaging of serotonin transporters in the non-human primate brain with the selective radioligand [123I]IDAM. Eur J Nucl Med 1999; 26: 854-861. (Pubitemid 29396997)
107. Kung MP, Hou C, Oya S, et al: Characterization of [123I]IDAM as a novel singlephoton emission tomography tracer for serotonin transporters. Eur J Nucl Med 1999; 26: 844-853.
108. Erlandsson K, Sivananthan T, Lui D, et al: Measuring SSRI occupancy of SERT using the novel tracer [123I]ADAM: a SPECT validation study. Eur J Nucl Med Mol Imaging 2005; 32: 1329-1336.
109. Sacher J, Asenbaum S, Klein N: Binding kinetics of 123I[ADAM] in healthy controls: a selective SERT radioligand. Int J Neuropsychopharmacol 2006; 10: 1-8.
110. Klein N, Sacher J, Geiss-Granadia T, et al: In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I] ADAM in healthy subjects administered different doses of escitalopram or citalopram. Psychopharmacology (Berl) 2006; 188: 263-272.
111. Chou YH, Yang BH, Chung MY, Chen SP, Su TP, Chen CC, Wang SJ: Imaging the serotonin transporter using (123)I-ADAM in the human brain. Psychiatry Res 2009; 172: 38-43.
112. Tamagnan GD, Brennerb E, Alagillea D, et al: Development of SPECT imaging agents for the norepinephrine transporters: [123I] INER. Bioorg Med Chem Lett 2007; 15: 533-537.
113. Yoritaka A, Ohizumi H, Tanaka S, Hattori N: Parkinson's disease with and without REM sleep behaviour disorder: are there any clinical differences? Eur Neurol 2009; 61: 164-170.
114. Miyamoto T, Miyamoto M, Suzuki K, Nishibayashi M, Iwanami M, Hirata K: 123I-MIBG cardiac scintigraphy provides clues to the underlying neurodegenerative disorder in idiopathic REM sleep behavior disorder. Sleep 2008; 31: 717-723.
115. Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE: Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord 2001; 16: 622-630.
116. Brooks DJ, Playford ED, Ibanez V, et al: Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study. Neurology 1992; 42: 1554-1560.
117. Toth C, Rajput M, Rajput AH: Anomalies of asymmetry of clinical signs in parkinsonism. Mov Disord 2004; 19: 151-157.
118. Rajput A, Robinson CA, Rajput AH: Essential tremor course and disability: a clinicopathologic study of 20 cases. Neurology 2004; 62: 932-936.
119. Marshall VL, Reininger CB, Marquardt M: Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord 2009; 24: 500-508.
120. Rocca W, Bower HJ, Ahlskog JE, et al: Increased risk of essential tremor in first-degree relatives of patients with Parkinson's disease. Mov Disord 2007; 22: 1607-1614. (Pubitemid 47477923)
121. Louis ED, Frucht SJ: Prevalence of essential tremor in patients with Parkinson's disease vs. Parkinson-plus syndromes. Mov Disord 2007; 22: 1402-1407.
122. Tan EK, Lee SS, Fook-Chong S, Lum SY: Evidence of increased odds of essential tremor in Parkinson's disease. Mov Disord 2008; 23: 993-997.
123. Spanaki C, Plaitakis A: Essential tremor in Parkinson's disease kindreds from a population of similar genetic background. Mov Disord 2009; 24: 1662-1668.
124. Asenbaum S, Pirker W, Angelberger P, Bencsits G, Pruckmayer M, Brucke T: [123I] beta-CIT and SPECT in essential tremor and Parkinson's disease. J Neural Transm 1998; 105: 1213-1228.
125. Benamer HT, Oertel WH, Patterson J, et al: Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders. Part 1. Baseline and 3-month observations. Mov Disord 2003; 18: 977-984.
126. Catafau AM and Tolosa E: Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord 2004; 19: 1175-1182.
127. Jennings DL, Seibyl JP, Oakes D, Eberly S, Murphy J, Marek K: [123I] beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. Arch Neurol 2004; 61: 1224-1229.
128. Eerola J, Tienari PJ, Kaakkola S, Nikkinen P, Launes J: How useful is [123I]beta-CIT SPECT in clinical practice? J Neurol Neurosurg Psychiatry 2005; 76: 1211-1216.
129. Parkinson Study Group: A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Neurology 2000; 55: 1540-1547.
130. Vlaar AM, van Kroonenburgh MJ, Kessels AG, Weber WE: Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurol 2007; 7: 27.
131. Vlaar Am, de Nijs T, Kessel AG, et al: Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. Eur Neurol 2008; 59: 258-1256
132. Isaias IU, Canesi M, Benti R, et al: Striatal dopamine transporter abnormalities in patients with essential tremor. Nucl Med Commun 2008; 29: 349-353.
133. Wang J, Jiang YP, Liu XD, et al: 99mTc-TRODAT-1 SPECT study in early Parkinson's disease and essential tremor. Acta Neurol Scand 2005; 112: 380-385.
134. Novellino F, Arabia G, Bagnato A, et al: Combined use of DAT-SPECT and cardiac MIBG scintigraphy in mixed tremors. Mov Disord 2009; 24: 2242-2248.
135. Antonini A. Berto P, Lopatriello S, et al: Cost-effectiveness of 123 I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy. Mov Disord 2008; 23: 2202-2209.
136. Stoessl AJ: Radionuclide scanning to diagnose Parkinson disease: is it cost-effective? Nat Clin Pract Neurol 2009; 5: 10-11.
137. Varrone A, Marek KL, Jennings D, Innis RB, Seibyl JP: [123I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy. Mov Disord 2001; 16: 1023-1032.
138. Varrone A, Pagani M, Salvatore E, et al: Identification by [99mTc]ECD SPECT of anterior cingulate hypoperfusion in progressive supranuclear palsy, in comparison with Parkinson's disease. Eur J Nucl Med Mol Imaging 2007; 34: 1071-1081.
139. Antonini A, Benti R, De Notaris R, et al: 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Neurol Sci 2003; 24: 149-150.
140. Scherfler C, Seppi K, Donnemiller E, et al: Voxel-wise analysis of [123I]-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. Brain 2005; 128: 1605-1612.
141. Zijlmans JCM, Daniel SE, Hughes AJ, Révész T, Lees AJ: Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov Disord 2004; 19: 630-640.
142. McKeith I, O'Brien J, Walker Z, et al: Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007; 6: 305-313.
143. Walker Z, Jaros E, Walker RW, et al: Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry 2007; 78: 1176-1181.
144. Lim SM, Katsifis A, Villemagne VL, et al: The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med 2009; 50: 1638-1645.
145. Rinne JO, Laine M, Kaasinen V, Norvasuo-Heilä MK, Någren K, Helenius H: Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia. Neurology 2002; 58: 1489-1493.
146. Sedaghat F, Gotzamani-Psarrakou A, Dedousi E, et al: Evaluation of dopaminergic function in frontotemporal dementia using I-FP-CIT single photon emission computed tomography. Neurodegener Dis 2007; 4: 382-385.
147. O'Sullivan SS, Burn DJ, Holton JL, Lees AJ: Normal dopamine transporter single photon-emission CT scan in corticobasal degeneration. Mov Disord 2008; 23: 2424-2426.
148. Klaffke S, Kuhn AA, Plotkin M, Amthauer H, Harnack D, Felix R, Kupsch A: Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration. Mov Disord 2006; 21: 1724-1727.
149. Kung HF, Guo YZ, Billings J, et al: Preparation and biodistribution of [125I]IBZM: a potential CNS D-2 dopamine receptor imaging agent. Int J Rad Appl Instrum 1988; 15: 195-201. (Pubitemid 18035185)
150. Tissingh G, Booij J, Winogrodzka A, van Royen EA, Wolters EC: IBZM-and CITSPECT of the dopaminergic system in parkinsonism. J Neural Transm Suppl 1997; 50: 31-37.
151. Halldin C, Gulyas B, Langer O, Farde L: Brain radioligands state of the art and new trends. Q J Nucl Med 2001; 45: 139-152.
152. Laruelle M, Abi-Dargham A, van Dyck CH, et al: SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 1995; 36: 1182-1190.
153. Murphy RA, Kung HF, Kung MP, Billings J: Synthesis and characterization of iodobenzamide analogues: potential D-2 dopamine receptor imaging agents. J Med Chem 1990; 33: 171-178
154. Pirker W, Asenbaum S, Wenger S, et al: Iodine-123-epidepride-SPECT: studies in Parkinson's disease, multiple system atrophy and Huntington's disease. J Nucl Med 1997; 38: 1711-1717.
155. Antonini A, Leenders KL, Vontobel P, et al: Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 1997; 120: 2187-2195.
156. Kim YJ, Ichise M, Ballinger JR, et al: Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord 2002; 17: 303-312.
157. Oyanagi C, Katsumi Y, Hanakawa T, et al: Comparison of striatal dopamine D2 receptors in Parkinson's disease and progressive supranuclear palsy patients using [123I] iodobenzofuran single-photon emission computed tomography. J Neuroimaging 2002; 12: 316-324.
158. Ghaemi M, Hilker R, Rudolf J, Sobesky J, Heiss WD: Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J Neurol Neurosurg Psychiatry 2002; 73: 517-523.
159. Knudsen GM, Karlsborg M, Thomsen G, et al: Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy. Eur J Nucl Med Mol Imaging 2004; 31: 1631-1638.
160. Schreckenberger M, Hagele S, Siessmeier T, et al: The dopamine D2 receptor ligand 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism. Eur J Nucl Med Mol Imaging. 2004; 31: 1128-1135.
161. Schwarz J, Tatsch K, Arnold G, et al: 123Iiodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism. Neurology 1992; 42: 556-561.
162. Hierholzer J, Cordes M, Schelosky L, et al: The differential diagnosis of Parkinson diseases-123I-IBZM-SPECT vs. The apomorphine test. Rofo 1993; 159: 86-90.
163. Antonini A, Vontobel P, Psylla M, et al: Complementary PET studies of the striatal dopaminergic system in Parkinson's disease. Arch Neurol 1995; 52: 1183-1192.
164. Pizzolato G, Cagnin A, Rossato A, et al: Striatal dopamine D2 receptor alterations and response to L-DOPA in Parkinson's disease. A [123I]IBZM SPET study. Adv Neurol 1996; 69: 467-473.
165. Hierholzer J, Cordes M, Venz S, et al: Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes. J Nucl Med 1998; 39: 954-960.
166. Booij J, Tissingh G, Winogrodzka A, van Royen EA: Imaging of the dopaminergic neurotransmission system using singlephoton emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 199; 26: 171-182.
167. Prunier C, Tranquart F, Cottier JP, et al: Quantitative analysis of striatal dopamine D2 receptors with 123 I-iodolisuride SPECT in degenerative extrapyramidal diseases. Nucl Med Commun 2001; 22: 1207-1214.
168. Buck A, Westera G, Sutter M, et al: Iodine-123-IBF SPECT evaluation of extrapyramidal diseases. J NucI Med 1995; 36: 1196-1200.
169. Walker Z, Costa DC, Janssen AG, Walker RW, Livingstone G, Katona CL: Dementia with Lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon emission tomography. Eur J Nucl Med 1997; 24: 609-614.
170. Plotkin M, Amthauer H, Klaffke S, et al: Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm 2005; 112; 677-692.
171. Eckert T, Tang C, Eidelberg D: Assessment of the progression of Parkinson's disease: a metabolic network approach. Lancet Neurol 2007; 6: 926-932. (Pubitemid 47405003)
172. Matsui H, Nishinaka K, Oda M, et al: Heterogeneous factors in dementia with Parkinson's disease: IMP-SPECT study. Parkinsonism Relat Disord 2006; 13: 174-181.
173. Wang SJ, Liu RS, Liu HC, et al: Technetium-99m hexamethylpropylene amine oxime single photon emission tomography of the brain in early Parkinson's disease: correlation with dementia and lateralization. Eur J Nucl Med 1993; 20: 339-344.
174. Markus HS, Lees AJ, Lennox G, Marsden CD, Costa DC: Patterns of regional cerebral blood flow in corticobasal degeneration studied using HMPAO SPECT: comparison with Parkinson's disease and normal controls. Mov Disord 1995; 10: 179-187.
175. Defebvre LJ, Leduc V, Duhamel A, et al: Technetium HMPAO SPECT study in dementia with Lewy bodies, Alzheimer's disease and idiopathic Parkinson's disease. J Nucl Med 1999; 40: 956-962.
176. Kageyama H, Kikuchi S, Tashiro K: Analysis of Parkinson's disease and related syndromes using 123I-IMP-SPECT with the ARG method. Nihonrinsho 2007; 55: 238-242.
177. Feigin A, Antonini A, Fukuda M, et al: Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism. Mov Disord 2002; 17: 1265-1270.
178. Bosman T, Van Laere K, Santens P: Anatomically standardised 99mTc-ECD brain perfusion SPET allows accurate differentiation between healthy volunteers, multiple system atrophy and idiopathic Parkinson's disease. Eur J Nucl Med Mol Imaging 2003; 30: 16-24.
179. Van Laere K, De Ceuninck L, Dom R, et al: Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-beta-CIT versus 99mTc-TRODAT-1. Eur J Nucl Med Mol Imaging 2004; 31: 1119-1127.
180. Antonini A, De Notaris R, Benti R, et al: Perfusion ECD/SPECT in the characterization of cognitive deficits in Parkinson's disease. Neurol Sci 2001; 22: 45-46.
181. Antonini A, Benti R, Righini A, Pezzoli G: Sensitivity and specificity of ECD/SPECT and high field (1,5T) MRI in the differential diagnosis between MSA and Parkinson's disease. Neurology 1999; 52:S351.
182. Derejko M, Šawek J, Wieczorek D, Brockhuis B, Dubaniewicz M, Lass P: Regional cerebral blood flow in Parkinson's disease as an indicator of cognitive impairment. Nucl Med Commun 2006; 27: 945-951.
183. Chang CC, Liu JS, Chang YY, Chang WN, Chen SS, Lee CH: (99m)Tc-ethyl cysteinate dimer brain SPECT findings in early stage of dementia with Lewy bodies and Parkinson's disease patients: a correlation with neuropsychological tests. Eur J Neurol 2008; 15: 61-65.
184. Rossi C, Frosini D, Volterrani D, et al: Differences in nigro-striatal impairment in clinical variants of early Parkinson's disease: evidence from a FP-CIT SPECT study. Eur J Neurol 2010; 17: 626-630.
185. Kurata T, Hayashi T, Murakami T, et al: Differentiation of PA from early PSP with different patterns of symptoms and CBF reduction. Neurol Res 2008; 30: 860-867.
186. Mito Y, Yoshida K, Yabe I, et al: Brain 3DSSP SPECT analysis in dementia with Lewy bodies, Parkinson's disease with and without dementia, and Alzheimer's disease. Clin Neurol Neurosurg 2005; 107: 396-400.
187. Firbank MJ, Burn DJ, McKeith IG, O'Brien JT: Longitudinal study of cerebral blood flow SPECT in Parkinson's disease with dementia, and dementia with Lewy bodies. Int J Geriatr Psychiatry 2005; 20: 776-782.
188. Tranfaglia C, Palumbo B, Siepi D, Sinzinger H, Parnetti L: Semi-quantitative analysis of perfusion of Brodmann areas in the differential diagnosis of cognitive impairment in Alzheimer's disease, fronto-temporal dementia and mild cognitive impairment. Hell J Nucl Med 2009; 12: 110-114.
189. Le Ber I, Guedj E, Gabelle A, et al: Demographic, neurological and behavioural characteristics and brain perfusion SPECT in frontal variant of frontotemporal dementia. Brain 2006; 129: 3051-3065.
190. Miller BL, Cumming JL, Villanueva-Meyer J, et al: Frontal lobe degeneration: clinical, neuropsychological, and SPECT characteristics. Neurology 1991; 41: 1374-1378.
191. Borroni B, Agosti C, Premi E, et al: The FTLD-modified Clinical Dementia Rating scale is a reliable tool for defining disease severity in frontotemporal lobar degeneration: evidence from a brain SPECT study. Eur J Neurol 2009, in press.
192. Starkstein SE, Migliorelli R, Teson A, et al: Specificity of changes in cerebral blood flow in patients with frontal lobe dementia. J Neurol Neurosurg Psychiatry 1994; 57: 790-796.
193. Didic M, Guisiano B, De Laforte C, Ceccaldi M, Poncet M: Identification of clinical subtypes of fronto-temporal dementia and cerebral blood flow on SPECT: preliminary results. Alzheimers Rep 1998; 1: 179-185.
194. Eckert T, Barnes A, Dhawan V, Frucht S, Gordon MF, Feigin AS, Eidelberg D: FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 2005; 26: 912-921.
195. Zhang L, Murata Y, Ishida R, Saitoh Y, Mizusawa H, Shibuya H: Differentiating between progressive supranuclear palsy and corticobasal degeneration by brain perfusion SPET. Nucl Med Commun 2001; 22: 767-772.
196. Yoshita M: Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci 1998; 155: 60-67.
197. Druschky A, Hilz MJ, Platsch G, et al: Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J Neurol Sci 2000; 175: 3-12.
198. Chung EJ, Lee WY, Yoon WT, Kim BJ, Lee GH: MIBG scintigraphy for differentiating Parkinson's disease with autonomic dysfunction from Parkinsonism-predominant multiple system atrophy. Mov Disord 2009; 24: 1650-1655.
199. Orimo S, Ozawa E, Nakade S, Hattori H, Tsuchiya K, Taki K, Takahashi A: [123I] meta-iodobenzylguanidine myocardial scintigraphy differentiates corticobasal degeneration from Parkinson's disease. Intern Med 2003; 42: 127-128.
200. Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H: 123I- metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999; 67: 189-194.
201. Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y: Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. J Neurol Neurosurg Psychiatry 2005; 76: 249-251.
202. Suzuki M, Kurita A, Hashimoto M, et al: Impaired myocardial 123 I-metaiodobenzylguanidine uptake in Lewy body disease: comparison between dementia with Lewy bodies and Parkinson's disease. J Neurol Sci 2006; 240: 15-19.
203. Yoshita M, Taki J, Yokoyama K, et al: Value of 123 I-MIBG radioactivity in the differential diagnosis of DLB from AD. Neurology 2006; 66: 1850-1854.
204. Scherfler C, Schwarz J, Antonini A, et al: Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord 2007; 22: 1229-1238.
205. Kalra S, Grosset DG, Benamer HT: Differentiating vascular parkinsonism from idiopathic Parkinson's disease: a systematic review. Mov Disord 2010; 25: 149-156.
206. Hardie RJ, Lees AJ: Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 1988; 51: 850-854.
207. Booij J, Speelman JD, Horstink HW, Wolters EC: The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPECT in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 2001; 28: 266-272.
208. Lavalaye J, Linszen DH, Booij J, et al: Dopamine transporter density in young patients with schizophrenia assessed with [123]FPCIT SPECT. Schizophr Res 2001; 47: 59-67.
209. Lorberboym M, Treves TA, Melamed E, Lampl Y, Hellmann M, Djaldetti R: [ 123 I] FP/CIT SPET imaging for distinguishing drug-induced parkinsonism from Parkinson's disease. Mov Disord 2006; 21: 510-514.
210. Tinazzi M, Ottaviani S, Isaias IU et al: [123I]FP-CIT SPET imaging in drug induced parkinsonism. Mov Disord 2008; 23: 1825-1829.
211. Tinazzi M, Antonini A, Bovi T, et al: Clinical and [123I]FP-CIT SPET imaging followup in patients with drug-induced parkinsonism. J Neurol 2009; 256: 910-915.
212. Antonini A: Imaging for early differential diagnosis of parkinsonism. Lancet Neurol 2010; 9: 130-131.